Trials On World’s First Viable Blood Substitute Aimed For India, U.S.
This article was originally published in PharmAsia News
Executive Summary
The first trials outside the United States for a HemoBioTech's blood substitute are planned for India where Phase I trials could begin this year. HemoBioTech said California-based Paragon Biomedical, which has an office in India, is to run the trials in both countries on the HemoTech artificial blood product and has applied for permission to run the clinical trials on what would be the world's first viable blood substitute. HemoBioTech hopes to test the product on patients with acute anemia, those requiring angioplasty and on trauma patients. (Click here for more